Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1799 results
October 2016
-
New Orbis Flying Eye Hospital helps fight blindness in China
During a three-week maiden voyage to the northern city of Shenyang, the plane's medical volunteers treated 124 patients and provided hands-on surgical training to 18 local doctors.
-
Media ReleaseNovartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II studyProgression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in…
-
Media ReleaseNovartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow upLatest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year…
-
Media ReleaseNovartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of careLEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups…
-
Chan Zuckerberg Initiative friends Novartis scientist in mission to conquer disease
Novartis’ Don Ganem tapped as a scientific advisor for the Chan Zuckerberg Biohub
-
Improving science communication in 3 easy steps
-
Digital health: providing opportunities for advocacy groups and a community for patients
Learn about how digital is changing the face of patient advocacy.
-
Media ReleaseNovartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global surveyGlobal survey of over 8,300 patients shows over half have not achieved clear skin (57%), with the majority taking the historical standard of care treatment[1]* Majority (84%) face…
-
Media ReleaseNovartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patientsCosentyx® delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years[1] New data show…
September 2016
-
Media ReleaseNovartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraineARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo…
-
Media ReleaseSandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challengesDespite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need Sandoz "HACk" - Healthcare Access Challenge - is…
-
Media ReleaseNovartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditionsIlaris® (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease These three simultaneous approvals conducted under FDA…
Pagination
- ‹ Previous page
- 1
- …
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- …
- 150
- › Next page